Philip Morris International (PMI) is selling inhaled drug specialist Vectura to Molex Asia Holdings for a fraction of the £1.1 billion ($1.45 billion) it paid for the business three years ago.

Colorado-based Sasaki has been tapped to lead Plan Baton Rouge III, the latest initiative aimed at advancing downtown Baton ...

Vectura's efforts to develop its own therapies met with mixed results, and the company was hit particularly hard in 2018 when it abandoned phase 3 drug candidate VR475 for severe uncontrolled asthma.

"The last quarter of the year saw greater movement in the market, with increased demand and willingness to invest. We received more inquiries late in 2024 and look forward to a market on the rise." Mi ...

The initiative was launched and signed on 20 February with participating companies including AstraZeneca, Skanska, Vectura Properties and Volvo Cars. Through the Handshake, they commit to increasing ...

Chief Executive Officer, Jacek Olczak, and Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 ...

Aerosol Delivery Devices Market Research Report In 2019, the aerosol delivery devices market is projected to reach $46.73 billion by 2027, ...

STAMFORD, CT--(BUSINESS WIRE)--Regulatory News: Philip Morris International Inc.’s (PMI) (NYSE: PM) Chief Executive Officer, Jacek Olczak, and Chief Financial Officer, Emmanuel Babeau, will ...